NeuroPace (NPCE) Stock Forecast & Price Target

Compare

125 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NPCE Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

NeuroPace

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NPCE Stock 12 Month Forecast

Average Price Target

$17.67

▲(59.62%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $17.67 with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 59.62% change from the last price of $11.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.04,13.575384615384614,14.11076923076923,14.646153846153846,15.18153846153846,15.716923076923077,16.252307692307692,16.787692307692307,17.323076923076922,17.85846153846154,18.393846153846155,18.92923076923077,19.464615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.04,13.396153846153846,13.752307692307692,14.108461538461539,14.464615384615385,14.820769230769232,15.176923076923078,15.533076923076923,15.889230769230771,16.245384615384616,16.601538461538464,16.95769230769231,17.313846153846157,{"y":17.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.04,13.267692307692307,13.495384615384614,13.723076923076922,13.95076923076923,14.178461538461537,14.406153846153845,14.633846153846154,14.861538461538462,15.089230769230769,15.316923076923077,15.544615384615383,15.772307692307692,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.99,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$17.67

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

17.43%

Upside

Reiterated

06/12/25

NeuroPace's overall stock score is primarily impacted by its financial performance challenges, including high leverage and cash flow issues. However, strong earnings call guidance, positive corporate events, and revenue growth potential provide a balanced outlook.

Priya SachdevaUBS

UBS

$18

Buy

62.60%

Upside

Reiterated

06/12/25

UBS Reaffirms Their Buy Rating on NeuroPace (NPCE)

Ross OsbornCantor Fitzgerald

Cantor Fitzgerald

$16

Buy

44.53%

Upside

Reiterated

06/12/25

Cantor Fitzgerald Sticks to Its Buy Rating for NeuroPace (NPCE)

Mike KratkyLeerink Partners

Leerink Partners

$16→$17

Buy

53.57%

Upside

Reiterated

06/06/25

Analysts Offer Insights on Healthcare Companies: MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and NeuroPace (NASDAQ: NPCE)

Frank TakkinenLake Street

Lake Street

$20

Buy

80.67%

Upside

Reiterated

06/05/25

NeuroPace (NPCE) Gets a Buy from Lake Street

Yi ChenH.C. Wainwright

H.C. Wainwright

$18

Buy

62.60%

Upside

Initiated

05/28/25

Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal

Rohin K PatelJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/27/25

Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential

Vik ChopraWells Fargo

Wells Fargo

$17

Buy

53.57%

Upside

Reiterated

05/27/25

NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement

Andrew RanieriMorgan Stanley

Morgan Stanley

Hold

-27.73%

Downside

Reiterated

11/13/24

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zai Lab (NASDAQ: ZLAB), NeuroPace (NASDAQ: NPCE) and CervoMed (NASDAQ: CRVO)

Michael PolarkWolfe Research

Wolfe Research

$16→$14

Buy

26.47%

Upside

Reiterated

08/14/24

NeuroPace Inc (NPCE) PT Lowered to $14 at Wolfe ResearchWolfe Research analyst Mike Polark lowered the price target on NeuroPace Inc (NASDAQ: NPCE) to $14.00 (from $16.00) while maintaining a Outperform rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

17.43%

Upside

Reiterated

06/12/25

Priya SachdevaUBS

UBS

$18

Buy

62.60%

Upside

Reiterated

06/12/25

UBS Reaffirms Their Buy Rating on NeuroPace (NPCE)

Ross OsbornCantor Fitzgerald

Cantor Fitzgerald

$16

Buy

44.53%

Upside

Reiterated

06/12/25

Cantor Fitzgerald Sticks to Its Buy Rating for NeuroPace (NPCE)

Mike KratkyLeerink Partners

Leerink Partners

$16→$17

Buy

53.57%

Upside

Reiterated

06/06/25

Analysts Offer Insights on Healthcare Companies: MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and NeuroPace (NASDAQ: NPCE)

Frank TakkinenLake Street

Lake Street

$20

Buy

80.67%

Upside

Reiterated

06/05/25

NeuroPace (NPCE) Gets a Buy from Lake Street

Yi ChenH.C. Wainwright

H.C. Wainwright

$18

Buy

62.60%

Upside

Initiated

05/28/25

Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal

Rohin K PatelJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/27/25

Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential

Vik ChopraWells Fargo

Wells Fargo

$17

Buy

53.57%

Upside

Reiterated

05/27/25

NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement

Andrew RanieriMorgan Stanley

Morgan Stanley

Hold

-27.73%

Downside

Reiterated

11/13/24

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zai Lab (NASDAQ: ZLAB), NeuroPace (NASDAQ: NPCE) and CervoMed (NASDAQ: CRVO)

Michael PolarkWolfe Research

Wolfe Research

$16→$14

Buy

26.47%

Upside

Reiterated

08/14/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeuroPace

1 Month

xxx

Success Rate

16/23 ratings generated profit

Average Return

+7.87%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.57% of your transactions generating a profit, with an average return of +7.87% per trade.

3 Months

xxx

Success Rate

15/23 ratings generated profit

Average Return

+26.66%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +26.66% per trade.

1 Year

Frank TakkinenLake Street

Success Rate

13/23 ratings generated profit

Average Return

+44.41%

reiterated a buy rating 12 days ago

Copying Frank Takkinen's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +44.41% per trade.

2 Years

xxx

Success Rate

14/23 ratings generated profit

Average Return

+56.89%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.87% of your transactions generating a profit, with an average return of +56.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NPCE Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NPCE has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NPCE average Analyst price target in the past 3 months is 17.67.

Each month's total comprises the sum of three months' worth of ratings.

NPCE Financial Forecast

NPCE Earnings Forecast

Next quarter’s earnings estimate for NPCE is -$0.22 with a range of -$0.27 to -$0.17. The previous quarter’s EPS was -$0.21. NPCE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.18% of the time in the same period. In the last calendar year NPCE has Outperformed its overall industry.

NPCE Sales Forecast

Next quarter’s sales forecast for NPCE is $23.09M with a range of $22.70M to $23.69M. The previous quarter’s sales results were $22.52M. NPCE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 56.92% of the time in the same period. In the last calendar year NPCE has Outperformed its overall industry.

NPCE Stock Forecast FAQ

What is NPCE’s average 12-month price target, according to analysts?

Based on analyst ratings, NeuroPace’s 12-month average price target is 17.67.

What is NPCE’s upside potential, based on the analysts’ average price target?

NeuroPace has 59.62% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NPCE a Buy, Sell or Hold?

NeuroPace has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is NeuroPace’s price target?

The average price target for NeuroPace is 17.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 59.62% Increase from the current price of $11.07.

What do analysts say about NeuroPace?

NeuroPace’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of NPCE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

NeuroPace (NPCE) Stock Forecast & Price Target

NPCE Analyst Ratings

NPCE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeuroPace

NPCE Analyst Recommendation Trends

NPCE Financial Forecast

NPCE Earnings Forecast

NPCE Sales Forecast

NPCE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts